会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • 3-AMINO-INDAZOLE OR 3-AMINO-4,5,6,7-TETRAHYDRO-INDAZOLE DERIVATIVES
    • 3-氨基吲哚或3-氨基-4,5,6,7-四氢吲哚衍生物
    • WO2010034657A1
    • 2010-04-01
    • PCT/EP2009/061966
    • 2009-09-15
    • F. HOFFMANN-LA ROCHE AGBENSON, Gregory, MartinBLEICHER, KonradFENG, SongGRETHER, UweKUHN, BerndMARTIN, Rainer, E.PLANCHER, Jean-MarcRICHTER, HansMARKUS, RudolphTAYLOR, Sven
    • BENSON, Gregory, MartinBLEICHER, KonradFENG, SongGRETHER, UweKUHN, BerndMARTIN, Rainer, E.PLANCHER, Jean-MarcRICHTER, HansMARKUS, RudolphTAYLOR, Sven
    • C07D231/56A61K31/416A61P3/06A61P3/10C07D401/12C07D407/12
    • C07D231/56C07D401/12C07D407/12
    • This invention relates to novel indazole derivatives of formula (I), wherein R 1 to R 7 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be use as medicaments. The compounds are selective modulators of the farnesoid-X-receptor, preferably agonists u j[ιe farnesoid-X-receptor (FXR) is a member of the nuclear hormone receptor superfamily of transcription factors. Diseases which are affected by FXR modulators include increased lipid and cholesterol levels, particularly high LDL-cholesterol, high triglycerides, low HDL-cholesterol, dyslipidemia, diseases of cholesterol absorption, atherosclerotic disease, peripheral occlusive disease, ischemic, stroke, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, diabetic nephropathy, obesity, cholesterol gallstone disease, cholestasis/fibrosis of the liver, non alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), psoriasis, cancer, particularly gastrointestinal cancer, osteoporosis, Parkinson's disease and Alzheimer's disease. Preferred diseases (and conditions) which are affected by FXR modulators are prevention or treatment of high LDL cholesterol levels high triglycerides, dyslipidemia, cholesterol gallstone disease, cancer, non-insulin dependent diabetes mellitus and metabolic syndrome. Particularly preferred diseases which arc affected by FXR modulators arc high LDL cholesterol, high triglyceride levels and dyslipidemia.
    • 本发明涉及式(I)的新的吲唑衍生物,其中R 1至R 7如说明书和权利要求书中所定义,以及其生理上可接受的盐。 这些化合物是FXR调节剂,可用作药物。 这些化合物是法呢基-X-受体的选择性调节剂,优选激动剂uj [法新颖-X-受体(FXR)是转录因子的核激素受体超家族的成员。 受FXR调节剂影响的疾病包括增加脂质和胆固醇水平,特别是高LDL-胆固醇,高甘油三酸酯,低HDL-胆固醇,血脂异常,胆固醇吸收疾病,动脉粥样硬化疾病,外周性闭塞性疾病,缺血性,中风,糖尿病,特别是非 - 胰岛素依赖性糖尿病,代谢综合征,糖尿病肾病,肥胖症,胆固醇胆结石疾病,肝脏胆汁郁积/纤维化,非酒精性脂肪性肝炎(NASH),非酒精性脂肪性肝病(NAFLD),牛皮癣,癌症,特别是胃肠癌, 骨质疏松症,帕金森病和阿尔茨海默病。 受FXR调节剂影响的首选疾病(和病症)是预防或治疗高LDL胆固醇水平高甘油三酯,血脂异常,胆固醇胆结石疾病,癌症,非胰岛素依赖性糖尿病和代谢综合征。 受FXR调节剂影响的特别优选的疾病具有高LDL胆固醇,高甘油三酯水平和血脂异常。